737 related articles for article (PubMed ID: 23816768)
1. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
[TBL] [Abstract][Full Text] [Related]
2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
3. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
4. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
Blick G; Khera M; Bhattacharya RK; Nguyen D; Kushner H; Miner MM
Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
[TBL] [Abstract][Full Text] [Related]
6. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
Aging Male; 2012 Mar; 15(1):14-21. PubMed ID: 22092151
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
8. Testim 1% testosterone gel for the treatment of male hypogonadism.
Bouloux P
Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
10. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
Miner M; Canty DJ; Shabsigh R
Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
[TBL] [Abstract][Full Text] [Related]
12. Review of Testim gel.
McNicholas T; Ong T
Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
[TBL] [Abstract][Full Text] [Related]
15. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
16. Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.
Rosen RC; Wu FC; Behre HM; Roehrborn CG; Schröder FH; Siami FS; Martha JF; Finn JD; Araujo AB
Aging Male; 2013 Mar; 16(1):1-7. PubMed ID: 23373674
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
18. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
19. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
